Population pharmacokinetic analysis of indinavir in HIV-infected patient treated with a stable antiretroviral therapy

Fundamental and Clinical Pharmacology

Volumn 19, Issue 3, 2005, Pages 373-383

  Brendel, Karl ^a   Legrand, Mayeule ^b   Taburet, Anne Marie ^c   Baron, Gabriel ^a   Goujard, Cécile ^c   Mentré, France ^a  

^a BICHAT HOSPITAL   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c BICÊTRE HOSPITAL   (France)

Author keywords

Indinavir; Population pharmacokinetics; Ritonavir; Therapeutic drug monitoring

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; RITONAVIR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARTMENT MODEL; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG MONITORING; DRUG RESPONSE; FEMALE; FRANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY DIAGNOSIS; LIVER DYSFUNCTION; MALE; MULTICENTER STUDY; NEPHROLITHIASIS; OPEN STUDY; POPULATION MODEL; PRIORITY JOURNAL; SIDE EFFECT; SIMULATION; TREATMENT FAILURE; VIRUS LOAD;

ADULT; AGED; ALGORITHMS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; AREA UNDER CURVE; BAYES THEOREM; COMPUTER SIMULATION; DATA INTERPRETATION, STATISTICAL; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; INDINAVIR; MALE; MIDDLE AGED; MODELS, STATISTICAL; POPULATION; SEX FACTORS;

EID: 20044381177     PISSN: 07673981     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2005.00315.x     Document Type: Article

References (38)

1. Palella F.J., Delaney K.M., Moorman A.C. et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. (1998) 338 853-860.
2. Jordan R., Gold L., Cummins C., Hyde C. Systematic review and meta-analysis of evidence for increasing numbers of drugs in antiretroviral combination therapy. Br. Med. J. (2002) 324 1-10.
3. Yeni P., Hammer S.M., Carpenter C.J. et al. Antiretroviral treatment for adult HIV infection: updated recommendations of the International AIDS Society-USA Panel. JAMA (2002) 288 222-235.
4. Lichterfeld M., Nischalke H.D., Bergmann F. et al. Long-term efficacy and safety of ritonavir/indinavir at 400/400 mg twice a day in combination with two nucleoside reverse transcriptase inhibitors as first line antiretroviral therapy. HIV Med. (2002) 3 37-43.
5. Polis M.A., Sidorov I.A., Yoder C. et al. Correlation between reduction in plasma HIV-1 RNA concentration one week after start of antiretroviral treatment and long-term efficacy. Lancet (2001) 358 1760-1765.
6. Condra J.H., Petropoulos C.J., Ziermann R., Schleif W.A., Shivaprakash M., Emini E.A. Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy. J. Infect. Dis. (2000) 182 758-765.
7. Salzberger B., Rockstroh J., Wieland U. et al. Clinical efficacy of protease inhibitor based antiretroviral combination therapy - a prospective cohort study. Eur. J. Med. Res. (1999) 4 449-455.
8. Launay O., Gerard L., Morand-Joubert L. et al. Nevirapine or lamivudine plus stavudine and indinavir: examples of 2-class vs. 3-class regimen for the treatment of human immunodeficiency virus type I. Clin. Infect. Dis. (2002) 35 1096-1105.
9. Duval X., Peytavin G., Albert I. et al. Determination of indinavir and nelfinavir trough plasma concentration efficacy thresholds according to virological response in HIV-infected patients. HIV Med. (2004) 5 307-313.
10. Dieleman J.P., Gyssens I.C., Van der Ende M.E., De Marie S., Burger D.M. Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients participating in the ADAM study. AIDS (2000) 14 59-98.
11. Reijers M.H., Weigel H.M., Hart A.A. et al. Toxicity and drug exposure in a quadruple drug regimen in HIV-1 infected patients participating in the ADAM study. AIDS (2000) 14 59-68.
12. Von Moltke L.L., Greenblatt D.J., Grassi J.M., Granda B.W., Duan S.X., Fogelman S.M. Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir. J. Clin. Pharmacol. (1998) 38 106-111.
13. Hsu A., Granneman G.R., Cao G., Carothers L., Japour A., Shourbagy T. Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers. Antimicrob. Agents Chemother. (1998) 42 2784-2791.
14. Saah A., Winchell G., Nessly M., Seniouk E., Rhodes R. Pharmacokinetic profile and tolerability of indinavir-ritonavir combinations in healthy volunteers. Antimicrob. Agents Chemoter. (2001) 45 2710-2721.
15. Arnaiz J.A., Mallolas J., Podzamczer D. et al. Continued indinavir vs. switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load. AIDS (2001) 17 831-840.
16. Zhou X.J., Havlir D.V., Richman D.D. et al. Plasma population pharmacokinetics and penetration into cerebrospinal fluid of indinavir in combination with zidovudine and lamivudine in HIV-1-infected patients. AIDS (2000) 14 2869-2876.
17. Letendre S.L., Capparelli E.V., Ellis R.J., McCutchan J.A. Indinavir population pharmacokinetics in plasma and cerebrospinal fluid. Antimicrob. Agents Chemother. (2000) 44 2173-2175.
18. Martin C., Sonnerborg A., Olof Svensson J., Stahle L. Indinavir-based treatment of HIV-1 infected patients: efficacy in the central nervous system. AIDS (1999) 13 1227-1232.
19. Pfister M., Labbé L., Hammer S.M. et al. Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398. Antimicrob. Agents Chemoter. (2003) 47 130-137.
20. Carrieri P., Cailleton V., Le Moing V. et al. The dynamic of adherence to highly active antiretroviral therapy: results from the French National APROCO Cohort. J. Acq. Immun. Def. Synd. (2001) 28 232-239.
21. Aymard G., Legrand M., Trichereau N., Diquet B. Determination of twelve antiretroviral agents in human plasma sample using reverse-phase high-performance liquid chromatography. J. Chromatogr. B (2000) 744 227-240.
22. Proust V., Toth K., Hulin A., Taburet A.M., Gimenez F., Singlas E. Simultaneous high-performance liquid chromatographic determination of the antiretroviral agents amprenavir, nelfinavir, ritonavir, saquinavir, delavirdine and efavirenz in human plasma. J. Chromatogr. B. (2000) 742 453-458.
23. Dailly E., Thomas L., Kergueris M.F., Jolliet P., Bourin M. High-performance liquid chromatographic assay to determine the plasma levels of HIV-protease inhibitors (amprenavir, nelfinavir, ritonavir, saquinavir) and the non-nucleoside reverse transcriptase inhibitor (nevirapine) after liquid. J. Chromatogr. B. (2001) 758 129-35.
24. Poirier J.M., Robidou P., Jaillon P. Determination of indinavir in plasma by solid-phase extraction and column liquid chromatography. Ther. Drug Monit. (1999) 21 404-410.
25. Bouley M., Briere C., Padoin C., Petitjean O., Tod M. Sensitive and rapid method for the simultaneous quantification of the HIV-protease inhibitors indinavir, nelfinavir, ritonavir and saquinavir in human plasma by reversed-phase liquid chromatography. Ther. Drug Monit. (2001) 23 56-60.
26. The United States Pharmacopoeia XXII: validation of compendial methods. USP Convention Inc., Rockville, 1990, pp. 1710.
27. Beal S.L. Ways to fit a PK model with some data below the quantification limit. J. Pharmacokinet. Pharmacodyn. (2001) 28 481-504.
28. Lee C.G., Gottesman M.M., Cardarelli C.O. et al. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry (1998) 37 3594-3601.
29. Washington C.B., Duran G.E., Man M.C., Sikic B.I., Blaschke T.F. Interaction of anti-HIV protease inhibitor with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells. J. Acq. Immun. Def. Synd. Hum. Retrovirol. (1998) 19 203-209.
30. Raffi F. Resistance to protease inhibitors: the role of the MDR gene. Presse Med. (2000) 29 2036-2037.
31. Csaika C., Marzolini C., Fattinger K. et al. Population pharmacokinetics and effects of indinavir in HIV infected patients. Clin. Pharmacol. Ther. (2003) 73 69.
32. Lin J.H., Chiba M., Chen I.W., Nishime J.A., Vastag K.J. Sex dependant pharmacokinetics of indinavir: in vivo and in vitro evidence. Drug Metab. Dispos. (1996) 24 1298-1306.
33. De Maat M.M., Huitema A.D., Mulder J.W., Meenhorst P.L., Van Gorp B.C., Beijnen J.H. Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals. Br. J. Clin. Pharmacol. (2002) 54 378-385.
34. Huitema A.D., Mathot R.A., Tibben M.M., Schellens J.H., Rodenhuis S., Beijnen J.H. Population pharmacokinetics of thioTEPA and its active metabolite TEPA in patients undergoing high-dose chemotherapy. Br. J. Clin. Pharmacol. (2001) 51 61-70.
35. Frame B., Koup J., Miller R., Lalonde R. Population pharmacokinetics of clinafloxacin in healthy volunteers and patients with infections: experience with heterogeneous pharmacokinetic data. Clin. Pharmacokinet. (2001) 40 307-315.
36. Karlsson M.O., Sheiner L.B. The importance of modeling interoccasion variability in population pharmacokinetic analyses. J. Pharmacokinet. Biopharm. (1993) 21 735-750.
37. Back D., Gatti G., Fletcher C. et al. Therapeutic drug monitoring in HIV infection: current status and future direction. AIDS (2002) 16 S5-S37.
38. Burger D., Hugen P., Reiss P. et al. Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naïve HTV-1-infected individuals. AIDS (2003) 17 1157-1165.